GERN News and Press, Geron Corporation From 12/11/25

2025-12-11 09:14:20 ET More on Geron Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help Geron Corporation (GERN) Q3 2025 Earnings Call Transcript Geron Corporation: Early Momentum, Strong Leadership Plus Clear Path To Growth - Why I Buy ...

Restructuring Supports RYTELO ® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutic...

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in lower-risk MDS Long-term follow-up analysi...

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points PR Newswire Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC , Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demons...

2025-11-07 08:15:36 ET ... Read the full article on Seeking Alpha For further details see: Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help

2025-11-05 14:21:58 ET More on Geron Geron Corporation (GERN) Q3 2025 Earnings Call Transcript Geron Corporation: Early Momentum, Strong Leadership Plus Clear Path To Growth - Why I Buy Making Money In Biotech Stocks Geron GAAP EPS of -$0.03 in-line, revenue ...

2025-11-05 14:21:14 ET Geron Corporation (GERN) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Dawn Schottlandt - Senior Vice President of Investor Relations & Corporate Affairs Harout Semerjian - CEO, President & Director Joseph Ei...

2025-11-05 07:02:52 ET More on Geron Geron Corporation: Early Momentum, Strong Leadership Plus Clear Path To Growth - Why I Buy Making Money In Biotech Stocks Geron: I Think We've Seen This Movie Before Geron Q3 2025 Earnings Preview Geron announces e...

Achieved $47.2 million in RYTELO® net product revenue in Q3 2025 Completed enrollment in Phase 3 IMpactMF clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis Strengthened leadership team with appointment of Chief Commercial Officer and additional key exe...

Curaleaf Holdings Inc (CURLF) is expected to report $-0.07 for Q3 2025 Southwest Gas Holdings Inc. (DE) (SWX) is expected to report $0.09 for Q3 2025 Terreno Realty Corporation (TRNO) is expected to report $0.65 for Q3 2025 Bio-Techne Corp (TECH) is expected to report $0.36 for Q1 202...